Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 343

1.

Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma.

Ghatalia P, Gordetsky J, Kuo F, Dulaimi E, Cai KQ, Devarajan K, Bae S, Naik G, Chan TA, Uzzo R, Hakimi AA, Sonpavde G, Plimack E.

J Immunother Cancer. 2019 May 28;7(1):139. doi: 10.1186/s40425-019-0621-1.

2.

Role of Checkpoint Inhibition in Localized Bladder Cancer.

Hahn NM, Necchi A, Loriot Y, Powles T, Plimack ER, Sonpavde G, Roupret M, Kamat AM.

Eur Urol Oncol. 2018 Aug;1(3):190-198. doi: 10.1016/j.euo.2018.05.002. Epub 2018 May 30. Review.

PMID:
31102620
3.

Conceptual Framework for Therapeutic Development Beyond Anti-PD-1/PD-L1 in Urothelial Cancer.

Grivas P, Drakaki A, Friedlander TW, Sonpavde G.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:284-300. doi: 10.1200/EDBK_237449. Epub 2019 May 17.

PMID:
31099684
4.

Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor.

Ferro M, Di Lorenzo G, Vartolomei MD, Bruzzese D, Cantiello F, Lucarelli G, Musi G, Di Stasi S, Hurle R, Guazzoni G, Busetto GM, Gabriele A, Del Giudice F, Damiano R, Perri F, Perdona S, Verze P, Borghesi M, Schiavina R, Almeida GL, Bove P, Lima E, Autorino R, Crisan N, Farhan ARA, Battaglia M, Russo GI, Ieluzzi V, Morgia G, De Placido P, Terracciano D, Cimmino A, Scafuri L, Mirone V, De Cobelli O, Shariat S, Sonpavde G, Buonerba C.

World J Urol. 2019 Apr 16. doi: 10.1007/s00345-019-02754-2. [Epub ahead of print]

PMID:
30993426
5.

Prostate cancer cells hyper-activate CXCR6 signaling by cleaving CXCL16 to overcome effect of docetaxel.

Kapur N, Mir H, Sonpavde GP, Jain S, Bae S, Lillard JW Jr, Singh S.

Cancer Lett. 2019 Jul 10;454:1-13. doi: 10.1016/j.canlet.2019.04.001. Epub 2019 Apr 8.

PMID:
30974114
6.

Rare Genitourinary Malignancies: Current Status and Future Directions of Immunotherapy.

McGregor BA, Sonpavde GP.

Eur Urol Focus. 2019 Mar 22. pii: S2405-4569(19)30086-0. doi: 10.1016/j.euf.2019.03.011. [Epub ahead of print] Review.

PMID:
30910391
7.

Use of Quantitative T2-Weighted and Apparent Diffusion Coefficient Texture Features of Bladder Cancer and Extravesical Fat for Local Tumor Staging After Transurethral Resection.

Lim CS, Tirumani S, van der Pol CB, Alessandrino F, Sonpavde GP, Silverman SG, Shinagare AB.

AJR Am J Roentgenol. 2019 Mar 12:1-10. doi: 10.2214/AJR.18.20718. [Epub ahead of print]

PMID:
30860885
8.

Mitochondrial localization, import, and mitochondrial function of the androgen receptor.

Bajpai P, Koc E, Sonpavde G, Singh R, Singh KK.

J Biol Chem. 2019 Apr 19;294(16):6621-6634. doi: 10.1074/jbc.RA118.006727. Epub 2019 Feb 21.

PMID:
30792308
9.

Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer.

Einstein DJ, Sonpavde G.

Curr Treat Options Oncol. 2019 Feb 11;20(2):12. doi: 10.1007/s11864-019-0609-6. Review.

PMID:
30741358
10.

Loss of FOXP3 and TSC1 Accelerates Prostate Cancer Progression through Synergistic Transcriptional and Posttranslational Regulation of c-MYC.

Wu L, Yi B, Wei S, Rao D, He Y, Naik G, Bae S, Liu XM, Yang WH, Sonpavde G, Liu R, Wang L.

Cancer Res. 2019 Apr 1;79(7):1413-1425. doi: 10.1158/0008-5472.CAN-18-2049. Epub 2019 Feb 7.

PMID:
30733194
11.

Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival?

Cole AP, Fletcher SA, Berg S, Nabi J, Mahal BA, Sonpavde GP, Nguyen PL, Lipsitz SR, Sun M, Choueiri TK, Preston MA, Kibel AS, Trinh QD.

Cancer. 2019 Apr 15;125(8):1319-1329. doi: 10.1002/cncr.31926. Epub 2019 Jan 11.

PMID:
30633323
12.

Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.

Sonpavde G, Agarwal N, Pond GR, Nagy RJ, Nussenzveig RH, Hahn AW, Sartor O, Gourdin TS, Nandagopal L, Ledet EM, Naik G, Armstrong AJ, Wang J, Bilen MA, Gupta S, Grivas P, Pal SK, Lanman RB, Talasaz A, Lilly MB.

Cancer. 2019 May 1;125(9):1459-1469. doi: 10.1002/cncr.31959. Epub 2019 Jan 8.

PMID:
30620391
13.

Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?

Berg S, D'Andrea D, Vetterlein MW, Cole AP, Fletcher SA, Krimphove MJ, Marchese M, Lipsitz SR, Sonpavde G, Noldus J, Shariat SF, Kibel AS, Trinh QD, Mossanen M.

Cancer. 2019 May 1;125(9):1449-1458. doi: 10.1002/cncr.31952. Epub 2019 Jan 8.

PMID:
30620387
14.

Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites.

Nassar AH, Umeton R, Kim J, Lundgren K, Harshman L, Van Allen EM, Preston M, Dong F, Bellmunt J, Mouw KW, Choueiri TK, Sonpavde G, Kwiatkowski DJ.

Clin Cancer Res. 2019 Apr 15;25(8):2458-2470. doi: 10.1158/1078-0432.CCR-18-3147. Epub 2018 Dec 28.

PMID:
30593515
15.

Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.

Grivas P, Mortazavi A, Picus J, Hahn NM, Milowsky MI, Hart LL, Alva A, Bellmunt J, Pal SK, Bambury RM, O'Donnell PH, Gupta S, Guancial EA, Sonpavde GP, Faltaos D, Potvin D, Christensen JG, Chao RC, Rosenberg JE.

Cancer. 2019 Feb 15;125(4):533-540. doi: 10.1002/cncr.31817. Epub 2018 Dec 20.

PMID:
30570744
16.

Examining the relationship between complications and perioperative mortality following radical cystectomy: a population-based analysis.

Mossanen M, Krasnow RE, Zlatev DV, Tan WS, Preston MA, Trinh QD, Kibel AS, Sonpavde G, Schrag D, Chung BI, Chang SL.

BJU Int. 2019 Jul;124(1):40-46. doi: 10.1111/bju.14636. Epub 2019 Apr 14.

PMID:
30499636
17.

Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories.

Mossanen M, Wang Y, Szymaniak J, Tan WS, Huynh MJ, Preston MA, Trinh QD, Sonpavde G, Kibel AS, Chang SL.

World J Urol. 2018 Nov 16. doi: 10.1007/s00345-018-2550-x. [Epub ahead of print]

PMID:
30446799
18.

Systemic treatments for metastatic urothelial carcinoma.

Lalani AA, Sonpavde GP.

Expert Opin Pharmacother. 2019 Feb;20(2):201-208. doi: 10.1080/14656566.2018.1544242. Epub 2018 Nov 9. Review.

PMID:
30412003
19.

Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing.

Slavin TP, Banks KC, Chudova D, Oxnard GR, Odegaard JI, Nagy RJ, Tsang KWK, Neuhausen SL, Gray SW, Cristofanilli M, Rodriguez AA, Bardia A, Leyland-Jones B, Janicek MF, Lilly M, Sonpavde G, Lee CE, Lanman RB, Meric-Bernstam F, Kurzrock R, Weitzel JN.

J Clin Oncol. 2018 Oct 19:JCO1800328. doi: 10.1200/JCO.18.00328. [Epub ahead of print]

PMID:
30339520
20.

SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer.

Merseburger AS, Apolo AB, Chowdhury S, Hahn NM, Galsky MD, Milowsky MI, Petrylak D, Powles T, Quinn DI, Rosenberg JE, Siefker-Radtke A, Sonpavde G, Sternberg CN.

World J Urol. 2019 Jan;37(1):95-105. doi: 10.1007/s00345-018-2486-1. Epub 2018 Sep 20. Review.

PMID:
30238401
21.

Treating Patients With Bladder Cancer: Is There an Ethical Obligation to Include Smoking Cessation Counseling?

Mossanen M, Caldwell J, Sonpavde G, Lehmann LS.

J Clin Oncol. 2018 Sep 13:JCO1800577. doi: 10.1200/JCO.18.00577. [Epub ahead of print] No abstract available.

PMID:
30212292
22.

Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.

Armstrong AJ, Lin P, Higano CS, Sternberg CN, Sonpavde G, Tombal B, Templeton AJ, Fizazi K, Phung D, Wong EK, Krivoshik A, Beer TM.

Ann Oncol. 2018 Nov 1;29(11):2200-2207. doi: 10.1093/annonc/mdy406.

PMID:
30202945
23.

An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma.

Choueiri TK, Michaelson MD, Posadas EM, Sonpavde GP, McDermott DF, Nixon AB, Liu Y, Yuan Z, Seon BK, Walsh M, Jivani MA, Adams BJ, Theuer CP.

Oncologist. 2019 Feb;24(2):202-210. doi: 10.1634/theoncologist.2018-0299. Epub 2018 Sep 6.

PMID:
30190302
24.

Immunotherapy for advanced penile cancer - rationale and potential.

McGregor B, Sonpavde G.

Nat Rev Urol. 2018 Dec;15(12):721-723. doi: 10.1038/s41585-018-0083-0. No abstract available.

PMID:
30166593
25.

Integrative Epigenetic and Gene Expression Analysis of Renal Tumor Progression to Metastasis.

Nam HY, Chandrashekar DS, Kundu A, Shelar S, Kho EY, Sonpavde G, Naik G, Ghatalia P, Livi CB, Varambally S, Sudarshan S.

Mol Cancer Res. 2019 Jan;17(1):84-96. doi: 10.1158/1541-7786.MCR-17-0636. Epub 2018 Aug 21.

PMID:
30131446
26.

A Role for De Novo Purine Metabolic Enzyme PAICS in Bladder Cancer Progression.

Chakravarthi BVSK, Rodriguez Pena MDC, Agarwal S, Chandrashekar DS, Hodigere Balasubramanya SA, Jabboure FJ, Matoso A, Bivalacqua TJ, Rezaei K, Chaux A, Grizzle WE, Sonpavde G, Gordetsky J, Netto GJ, Varambally S.

Neoplasia. 2018 Sep;20(9):894-904. doi: 10.1016/j.neo.2018.07.006. Epub 2018 Aug 15.

27.

Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma.

Sonpavde GP, Mariani L, Lo Vullo S, Raggi D, Giannatempo P, Bamias A, Crabb SJ, Bellmunt J, Yu EY, Niegisch G, Vaishampayan UN, Theodore C, Berthold DR, Srinivas S, Sridhar SS, Plimack ER, Rosenberg JE, Powles T, Galsky MD, Necchi A.

J Urol. 2018 Dec;200(6):1207-1214. doi: 10.1016/j.juro.2018.07.035. Epub 2018 Sep 4.

PMID:
30012366
28.

Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era.

Fletcher SA, Harmouch SS, Krimphove MJ, Cole AP, Berg S, Gild P, Preston MA, Sonpavde GP, Kibel AS, Sun M, Choueiri TK, Trinh QD.

World J Urol. 2018 Nov;36(11):1767-1774. doi: 10.1007/s00345-018-2371-y. Epub 2018 Jun 14.

PMID:
29948050
29.

Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer?

Brown LC, Sonpavde G, Armstrong AJ.

Prostate Cancer Prostatic Dis. 2018 Sep;21(3):419-430. doi: 10.1038/s41391-018-0049-6. Epub 2018 Jun 1.

PMID:
29858595
30.

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2).

Rosenberg JE, Hahn NM, Regan MM, Werner L, Alva A, George S, Picus J, Alter R, Balar A, Hoffman-Censits J, Grivas P, Lauer R, Guancial EA, Hoimes C, Sonpavde G, Albany C, Stein MN, Breen T, Jacobs C, Anderson K, Bellmunt J, Lalani AA, Pal S, Choueiri TK.

Br J Cancer. 2018 May;118(11):1434-1441. doi: 10.1038/s41416-018-0087-9. Epub 2018 May 16.

31.

Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States.

Galsky MD, Pal SK, Lin SW, Ogale S, Zivkovic M, Simpson J, Derleth C, Schiff C, Sonpavde G.

Bladder Cancer. 2018 Apr 26;4(2):227-238. doi: 10.3233/BLC-170149.

32.

Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study.

Gordon JA, Buonerba C, Pond G, Crona D, Gillessen S, Lucarelli G, Rossetti S, Dorff T, Artale S, Locke JA, Bosso D, Milowsky MI, Witek MS, Battaglia M, Pignata S, Cherhroudi C, Cox ME, De Placido P, Ribera D, Omlin A, Buonocore G, Chi K, Kollmannsberger C, Khalaf D, Facchini G, Sonpavde G, De Placido S, Eigl BJ, Di Lorenzo G.

Oncotarget. 2018 Apr 13;9(28):19861-19873. doi: 10.18632/oncotarget.24888. eCollection 2018 Apr 13.

33.

Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy.

Sonpavde G, Pond GR, Rosenberg JE, Choueiri TK, Bellmunt J, Regazzi AM, Mullane SA, Necchi A, Raggi D, Lee JL, Lee S, Simpson J, Derleth CL, Lin SW, Bajorin DF.

Clin Genitourin Cancer. 2018 Aug;16(4):e961-e967. doi: 10.1016/j.clgc.2018.03.016. Epub 2018 Apr 6.

PMID:
29706503
34.

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.

Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, Sonpavde G, Sternberg CN, Yegnasubramanian S, Antonarakis ES.

Eur Urol. 2019 Jan;75(1):88-99. doi: 10.1016/j.eururo.2018.03.028. Epub 2018 Apr 16. Review.

PMID:
29673712
35.

Improving the Cost Efficiency of PD-1/PD-L1 Inhibitors for Advanced Urothelial Carcinoma: A Major Role for Precision Medicine?

Sonpavde G, Dranitsaris G, Necchi A.

Eur Urol. 2018 Jul;74(1):63-65. doi: 10.1016/j.eururo.2018.03.015. Epub 2018 Apr 10. No abstract available.

PMID:
29653886
36.

Current Staging Strategies for Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Cell Carcinoma.

Mossanen M, Chang SL, Kimm S, Sonpavde GP, Kibel AS.

Urol Clin North Am. 2018 May;45(2):143-154. doi: 10.1016/j.ucl.2017.12.001. Review.

PMID:
29650131
37.

Utility of cell-free nucleic acid and circulating tumor cell analyses in prostate cancer.

Gourdin T, Sonpavde G.

Asian J Androl. 2018 May-Jun;20(3):230-237. doi: 10.4103/aja.aja_1_18. Review.

38.

Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.

Agarwal N, Pal SK, Hahn AW, Nussenzveig RH, Pond GR, Gupta SV, Wang J, Bilen MA, Naik G, Ghatalia P, Hoimes CJ, Gopalakrishnan D, Barata PC, Drakaki A, Faltas BM, Kiedrowski LA, Lanman RB, Nagy RJ, Vogelzang NJ, Boucher KM, Vaishampayan UN, Sonpavde G, Grivas P.

Cancer. 2018 May 15;124(10):2115-2124. doi: 10.1002/cncr.31314. Epub 2018 Mar 8.

39.

The effect of treatment at minority-serving hospitals on outcomes for bladder cancer.

Fletcher SA, Gild P, Cole AP, Vetterlein MW, Kibel AS, Choueiri TK, Sonpavde GP, Preston MA, Pucheril D, Menon M, Sun M, Lipsitz SR, Trinh QD.

Urol Oncol. 2018 May;36(5):238.e7-238.e17. doi: 10.1016/j.urolonc.2018.01.010. Epub 2018 Feb 15.

PMID:
29454591
40.

Taxane chemotherapy vs antiandrogen agents as first-line therapy for metastatic castration-resistant prostate cancer.

Sonpavde G, Huang A, Wang L, Baser O, Miao R.

BJU Int. 2018 Jun;121(6):871-879. doi: 10.1111/bju.14152. Epub 2018 Mar 6.

41.

Effect of Single-agent Daily Prednisone on Outcomes and Toxicities in Metastatic Castration-resistant Prostate Cancer: Pooled Analysis of Prospective Studies.

Ghatalia P, Pond GR, Templeton AJ, Sonpavde G.

Clin Genitourin Cancer. 2018 Apr;16(2):e277-e287. doi: 10.1016/j.clgc.2017.12.006. Epub 2017 Dec 27. Review.

PMID:
29352714
42.

Overview of Current and Future Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma.

Nandagopal L, Naik G, Sonpavde G.

Curr Treat Options Oncol. 2018 Jan 18;19(1):2. doi: 10.1007/s11864-018-0522-4. Review.

PMID:
29349592
43.

The prospects for combination therapy with capecitabine in the rapidly evolving treatment landscape of renal cell carcinoma.

Bilen MA, Carlisle JW, Sonpavde G.

Expert Opin Investig Drugs. 2018 Feb;27(2):163-170. doi: 10.1080/13543784.2018.1427731. Epub 2018 Jan 24. Review.

PMID:
29323560
44.

Taxane-based Combination Therapies for Metastatic Prostate Cancer.

Corn PG, Agarwal N, Araujo JC, Sonpavde G.

Eur Urol Focus. 2017 Dec 20. pii: S2405-4569(17)30265-1. doi: 10.1016/j.euf.2017.11.009. [Epub ahead of print] Review.

PMID:
29275145
45.

Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes.

Galsky MD, Wang H, Hahn NM, Twardowski P, Pal SK, Albany C, Fleming MT, Starodub A, Hauke RJ, Yu M, Zhao Q, Sonpavde G, Donovan MJ, Patel VG, Sfakianos JP, Domingo-Domenech J, Oh WK, Akers N, Losic B, Gnjatic S, Schadt EE, Chen R, Kim-Schulze S, Bhardwaj N, Uzilov AV.

Eur Urol. 2018 May;73(5):751-759. doi: 10.1016/j.eururo.2017.12.001. Epub 2017 Dec 13.

PMID:
29248319
46.

Promising immunotherapy for prostate cancer.

Henegan JC, Sonpavde G.

Expert Opin Biol Ther. 2018 Feb;18(2):109-120. doi: 10.1080/14712598.2018.1406916. Epub 2017 Dec 12. Review.

PMID:
29231062
47.

Emerging first line treatment options for bladder cancer: a review of phase II and III therapies in the pipeline.

Jamy O, Sonpavde G.

Expert Opin Emerg Drugs. 2017 Dec;22(4):347-355. doi: 10.1080/14728214.2017.1416092. Epub 2017 Dec 19. Review.

PMID:
29226734
48.

C-statistic: A brief explanation of its construction, interpretation and limitations.

Caetano SJ, Sonpavde G, Pond GR.

Eur J Cancer. 2018 Feb;90:130-132. doi: 10.1016/j.ejca.2017.10.027. Epub 2017 Dec 5. No abstract available.

PMID:
29221899
49.

JAVELIN: avelumab another spear to fight urothelial carcinoma.

Lalani AA, McGregor BA, Sonpavde GP, Choueiri TK.

Lancet Oncol. 2018 Jan;19(1):5-7. doi: 10.1016/S1470-2045(17)30901-4. Epub 2017 Dec 5. No abstract available.

PMID:
29217289
50.

Update of systemic immunotherapy for advanced urothelial carcinoma.

Gartrell BA, He T, Sharma J, Sonpavde G.

Urol Oncol. 2017 Dec;35(12):678-686. doi: 10.1016/j.urolonc.2017.09.021. Epub 2017 Oct 25. Review.

PMID:
29079131

Supplemental Content

Loading ...
Support Center